Los Angeles-Area A2 Biotherapeutics (www.a2bio.com) announced the closing of its $71.5M Series B financing round to fund the advancement of its Tmod (engineered T-cell module) platform that reportedly combines activating and blocking mechanisms to kill tumor cells and protect normal cells.
and related near-term product candidates.  Series B investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment. Here are links to related news stories.

https://www.businesswire.com/news/home/20201006005044/en/A2-Biotherapeutics-Closes-71.5M-Series-B-to-Begin-Clinical-Development-of-Its-Potentially-Transformative-Selective-Tumor-Cell-Therapeutics

https://www.prnewswire.com/news-releases/a2-biotherapeutics-closes-71-5m-series-b-to-begin-clinical-development-of-its-potentially-transformative-selective-tumor-cell-therapeutics-301145221.html

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Dan Shores Dan Shores

Dan Shores is a Partner at Rothwell Figg and is a founder of its Boston office. He is passionate about helping his clients build robust patent portfolios, litigate matters (both as plaintiffs and defendants in the U.S. District Courts and in IPR and…

Dan Shores is a Partner at Rothwell Figg and is a founder of its Boston office. He is passionate about helping his clients build robust patent portfolios, litigate matters (both as plaintiffs and defendants in the U.S. District Courts and in IPR and other post-grant proceedings), protect trade secrets, negotiate strategic collaborations, conduct due diligence and landscape investigations, and prepare for success in funding rounds and exits. Dan is a problem-solver who excels at deciphering key translational aspects of a broad array of technologies to maximize leverage in the context of clients’ desired implementation of such technologies whether as participants in dynamic markets or as first movers. Dan is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts. Dan lives in Boston with his wife Lindsay, their daughter Audrey, and their two English Bulldogs Jarves and Rosie.

Read more about Dan ShoresDan's Linkedin Profile
Show more Show less
Related Posts
 CRISPR and Agriculture
February 7, 2025
 The Future of Food: Regulatory and Patent Landscape of Genome Editing in Food Technology
October 15, 2024
 This Summer in Artificial Intelligence: Newly Released USPTO Guidance and Exemplary Worldwide Inventorship Updates
July 22, 2024